Exclusive

Publication

Byline

Why Policybazaar-backed PB Health is doubling down on hospitals

New Delhi, Sept. 22 -- PB Health, backed by PB Fintech (the parent company of online insurance marketplace Policybazaar's parent company) plans to invest about Rs.10,000 crore over the next few years ... Read More


Mint Explainer | Why counterfeit drugs are getting harder to detect in India

New Delhi, Sept. 14 -- Two major instances of counterfeit life-saving drugs being uncovered in the past two weeks have raised concern among consumers. Industry executives say counterfeiting is a growi... Read More


HRV Pharma bets Rs.150 crore on peptides, high-potency oncology APIs

New Delhi, Sept. 7 -- Hyderabad-based drugmaker HRV Pharma is expanding its peptides and oncology capabilities through manufacturing partnerships, seeking to tap niche and complex segments while keepi... Read More


PI Industries bets on innovation-led growth as agrochem headwinds mount

New Delhi, Sept. 4 -- Amid a challenging global environment, agrochemical major PI Industries is betting on novel molecules developed in-house and is branching out into manufacturing capabilities for ... Read More


Sun Pharma signs deal with US government to reduce drug prices

New Delhi, Sept. 1 -- Drug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other ... Read More


Tata Capital Healthcare Fund leads $30 million investment in Tenet Diagnostics

New Delhi, Aug. 17 -- Tata Capital Healthcare Fund (TCHF) and Swiss investor Blue Earth Capital AG on Monday announced a $30 million investment in Tenet Diagnostics for an undisclosed equity stake. Th... Read More


Apollo Hospitals beats estimates for Q1FY27, net profit up 34%

New Delhi, Aug. 12 -- Apollo Hospitals Enterprise Ltd beat street estimates for the June quarter as high speciality volumes continued to boost growth, and the hospital chain continued its capacity exp... Read More


US generics tariffs more negotiation tactic than real threat: Biocon's Kiran Mazumdar-Shaw

New Delhi, Aug. 7 -- Biocon is not rushing to react to proposed US tariffs on generic drugs in its largest market as it sees the move as a negotiation tactic rather than a real threat, executive chair... Read More


Metropolis ramps up small-town presence to capture shift toward organized healthcare

New Delhi, Aug. 6 -- Diagnostics major Metropolis Healthcare is accelerating its expansion into India's tier-II and tier-III markets, capitalizing on a multi-year investment push designed to capture a... Read More


US generics drag weighs on Sun Pharma

Mumbai, Aug. 1 -- Sun Pharmaceutical Industries, India's biggest drugmaker by market capitalization, missed Street expectations in the June quarter as weakness in its US generics business weighed on p... Read More